The Founders of PharmaJet have been caregivers for decades — both helping provide health services in remote villages within the developing world, and treating patients in clinics with the highest of standards. With the World Health Organization’s (WHO) guidelines in mind, the Founders created a needle-free injection technology that is simple, robust, and inexpensive. Unlike the metal-tip high-pressure injectors long considered to be standard for mass vaccination programs which were recently removed from the market due to demonstrated cross infection with hepatitis-B among patients, and unlike reusable needle free devices commonly used for the delivery of therapeutics like insulin — the PharmaJet device was designed to prevent such cross-contamination and re-use, and make sure that without external power sources and limited healthcare education it could be safely used in any environment.

Today, PharmaJet’s group of dedicated and brilliant engineers, scientists, and business people are building on the core technology by developing a suite of complimentary injection technologies that are capable of delivering consistent, safe, reliable, comfortable injections — whether for standard vaccines in standard places on the body, or for specific vaccines and therapeutics that may be fragile or require delivery specific to a location on or within the body. Testing underway with collaboration partners located in all geographical areas of the world is aimed at a broad range of injectable medicines--from existing EPI standard vaccines, to next generation vaccines, and new vaccines and therapeutics — for both animal or human population usage — for standard and reduced-dosage formats — in field-filled and pre-filled formats. Completion of these tests will provide for PharmaJet’s technology to be made available in multiple countries and markets around the world, together with the vaccines, so that it gets to the right place at the right time where it is most needed.

With evidence of the world’s disease burden causing massive loss in human and animal productivity that affects us all, and the danger and expense associated with needle-stick, and the need for improved immune response (both faster and better), the time for PharmaJet’s technology has arrived.

Executive Team

Kathy Callender, Founder and President
A healthcare professional with more than 35 years of experience in clinical and patient treatment and practice management — both in the field and in the clinic — she is intimately familiar with the science and quality assurance that goes into the device creation and production to meet FDA, ISO and other regulatory requirements. Kathy’s passion for helping improve world health through creation of a highly effective needle-free technology appropriate for the developing world continues to drive the Company’s mission forward. Kathy has a B.S. from the University of Missouri.

Michael Royals, Chief Science Officer
A research veterinarian (DVM) by education with 12 years experience creating human medical devices Dr. Royals provides a keen interface with PharmaJet collaboration partners. Prior to joining PharmaJet, Dr. Royals founded Applied Antigens and Bio-Logistics Preclinical, served as a laboratory animal veterinarian at Colorado State University, and was Vivarium Director and GLP Study monitor at B. Braun Medical. His experience provides for broad interface between PharmaJet’s engineering team and pharmaceutical manufacturers working in the lab, in the field, and preparing to commercialize their vaccines and therapeutics with PharmaJet’s devices.

Ron Bauer, Director of Regulatory and Quality Control
With more than 25 years of progressive engineering, Quality Systems, and Regulatory Affairs management, Ron is skilled at guiding PharmaJet through its various regulatory applications in multiple markets around the world, while providing for assurance that FDA, ISO and other regulatory standards are met. Ron holds a BS in engineering from Metropolitan State University.

John Bingham, Design and Production Chief
Having more than 16 years experience in industrial design, mold design and manufacturing, product design and development—including owning two mold manufacturing companies — John oversees the design and development of PharmaJet’s devices, and monitors production partners to ensure that quality standards are met.

Board of Directors

Heather Potters, Chairman, Investor, Angel, Fund Manager
Responsible for managing shareholder interface, fundraising, legal and business development, partner and investment decisions at PharmaJet, Heather brings a background of 17 years experience in private equity fund and investment management. Heather’s international investment experience has touched on more than 15 jurisdictions, which adds support to PharmaJet’s global activities. She holds an MBA from The Wharton School and B.A. in International Management from Claremont McKenna College.

Gary Calmenson, Investor, Entrepreneur, Angel
Gary is an accomplished serial entrepreneur and angel investor with more than 38 years experience in financing, manufacturing, retail, importing, exporting, and other businesses. In additional to being a successful real estate developer, owner and manager, Gary has served on several boards of companies and banks. He is a graduate of New York University.

Linda Sonntag, Scientist, Entrepreneur, Venture Capitalist
Using her science and business acumen, Linda was the first woman CEO of a publicly held biotechnology company, SyStemix Inc (NYSE: NVS), and negotiated a $392 million investment in the company from Sandos (now Novartis). From South Africa, she has a PhD in biochemistry from the University of Witwatersrand and post graduate experience with the founder of Genentech, Harvard Business School, and MIT’s Sloan School of Management. She was a visiting scientist at the Weizmann Institute of Science, and General Partner of Axiom Venture Partners, which had an investment focus in medical, health care, and media and communications.

Markus Pedriks, Investor, Entrepreneur, Angel
With more than 20 years of telecommunications and media-company investment and operating experience, in Western and Eastern Europe, Markus has been involved as an investor/founder and/or shareholder of 22 distinct mobile properties, among other companies. Familiar with investments in several other kinds of markets — health, entertainment, retail, and real estate—Markus has significant operating experience that he applies to his investment activities. He holds an MBA from IMD in Lausanne, and a BA in Economics from McGill University in Montreal, and is a Canadian and Estonian national.